Immorta Bio's Revolutionary SenoVax™ Presentation
Immorta Bio is set to unveil promising results related to its groundbreaking SenoVax™ product at an esteemed symposium dedicated to the advancement of cancer immunotherapy. The poster presentation will spotlight the success achieved in experiments targeting lung, breast, pancreatic, and brain cancers.
Overview of SenoVax™
SenoVax™, a unique senolytic immunotherapy, is designed to selectively eliminate senescent cells that are implicated in cancer development and progression. Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, emphasized the significance of their research, stating, "We will share compelling data showing cancer regression in animal models with glioma, lung, breast, and pancreatic cancers utilizing our innovative SenoVax approach.”
The Upcoming Symposium
The Society for Immunotherapy of Cancer (SITC) symposium will be held in San Diego, showcasing cutting-edge research aimed at transforming cancer treatment. Immorta Bio's participation underscores the importance of their findings, particularly how targeting senescent cells can change the paradigm of cancer therapy.
Collaboration with leading institutions including the University of California San Diego and George Washington University has been pivotal in the development and validation of SenoVax™. This work positions Immorta Bio at the forefront of cancer research.
Statements from Leadership
Dr. Boris Reznik, Chairman and CEO of Immorta Bio, expressed his enthusiasm for the opportunity to present at the symposium. He noted, "Being chosen to present to such a distinguished audience speaks volumes about the potential of our paradigm-shifting approach. By targeting senescent cells, we are not just addressing cancer but also potentially reducing the overall burden of cellular senescence, which may provide anti-aging benefits to treated patients.”
About Immorta Bio
Immorta Bio Inc. is a pioneering scientific longevity company that focuses on addressing aging-related diseases through innovative technologies. Their mission, encapsulated in their motto “Treating Diseases of Aging and Treating Aging as Disease™,” aims to tackle significant medical challenges posed by advanced cancers and age-associated conditions. For more information about Immorta Bio’s initiatives and research efforts, visit their official website.
Company Contact
For inquiries, please contact Dr. Boris Reznik at Immorta Bio through their official site. You can also connect with them via social media for the latest updates on their research and developments.
Frequently Asked Questions
What is SenoVax™?
SenoVax™ is a first-in-class senolytic immunotherapy that targets and eliminates senescent cells associated with cancer.
Where will the presentation take place?
The presentation will be at the Society for Immunotherapy of Cancer symposium in San Diego.
What types of cancers are being studied with SenoVax™?
The studies focus on lung, breast, pancreatic, and brain cancers.
Who is leading the research at Immorta Bio?
The research is led by Dr. Thomas Ichim and overseen by Dr. Boris Reznik.
What is the goal of Immorta Bio?
Immorta Bio aims to treat age-related diseases and improve longevity through innovative therapeutic approaches.